Cheung, Ka Shing
Mak, Lung Yi
Lam, Lok Ka
Fung, James
Liu, Fen
Seto, Wai Kay
Yuen, Man Fung
Article History
Received: 28 January 2021
Accepted: 23 April 2021
First Online: 14 May 2021
Declarations
:
: W. K. Seto is an advisory board member of AbbVie and Gilead Sciences, and received speaker fees from AbbVie, Gilead Sciences, and Mylan. J. Fung received research funding from Novartis. M. F. Yuen is advisory board member and received speaker’s fees from AbbVie, Janssen, Biocartis NV, Bristol Myers Squibb, Fujirebio Incorporation, Gilead Sciences, Merck Sharp, and Dohme, Sysmex Corporation. M. F. Yuen does consulting for Aligos Pharmaceuticals, Assembly Biosciences, Arbutus Biopharma, Dicerna Pharmaceuticals, Clear-B Therapeutics, GlaxoSmithKline, Immunocore, Springbank Pharmaceuticals and also received research funding from Bristol Myers Squibb and Gilead Sciences. L. Y. Mak is advisory board member of Gilead Sciences. Ka Shing Cheung, Lok Ka Lam and Fen Liu have no conflicts of interest.
: This study did not involve animal research.
: This is a retrospective cohort study and has been approved by Institutional Review Board, University of Hong Kong and West Cluster of Hospital Authority, Hong Kong.
: Participate identity was anonymized in this study.
: This is not a clinical trial.